In the latest session, Royalty Pharma plc (NASDAQ: RPRX) closed at $29.93 down -1.35% from its previous closing price of $30.34. In other words, the price has decreased by -$0.41 from its previous closing price. On the day, 2680910 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Royalty Pharma plc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 26.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.41. For the most recent quarter (mrq), Quick Ratio is recorded 7.90 and its Current Ratio is at 7.90. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.94.
On May 13, 2022, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $53.
On April 27, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $56.Goldman initiated its Buy rating on April 27, 2022, with a $56 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 04 when RIGGS RORY B sold 35,702 shares for $27.55 per share. The transaction valued at 983,504 led to the insider holds 20,099 shares of the business.
RIGGS RORY B sold 199,098 shares of RPRX for $5,532,276 on Jan 03. The Director now owns 55,801 shares after completing the transaction at $27.79 per share. On Jan 02, another insider, RIGGS RORY B, who serves as the Director of the company, sold 235,200 shares for $28.52 each. As a result, the insider received 6,707,081 and left with 254,899 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RPRX now has a Market Capitalization of 13.37B and an Enterprise Value of 18.27B. As of this moment, Royalty’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.80, and their Forward P/E ratio for the next fiscal year is 7.38. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.69. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.68 while its Price-to-Book (P/B) ratio in mrq is 2.05. Its current Enterprise Value per Revenue stands at 7.76 whereas that against EBITDA is 9.68.
Stock Price History:
Over the past 52 weeks, RPRX has reached a high of $38.19, while it has fallen to a 52-week low of $25.92. The 50-Day Moving Average of the stock is 28.94, while the 200-Day Moving Average is calculated to be 29.31.
Shares Statistics:
For the past three months, RPRX has traded an average of 2.91M shares per day and 3.61M over the past ten days. A total of 446.69M shares are outstanding, with a floating share count of 378.88M. Insiders hold about 15.18% of the company’s shares, while institutions hold 68.61% stake in the company. Shares short for RPRX as of Feb 15, 2024 were 11.5M with a Short Ratio of 3.95, compared to 10.19M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.57% and a Short% of Float of 2.69%.
Dividends & Splits
According to the company, the forward annual dividend rate for RPRX is 0.81, from 0.80 in the trailing year. Against a Trailing Annual Dividend Yield of 2.64%, it implies a Forward Annual Dividend Yield of 2.81%.
Earnings Estimates
There are 4 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.88 for the current quarter, with a high estimate of $0.99 and a low estimate of $0.81, while EPS last year was $1.6. The consensus estimate for the next quarter is $0.88, with high estimates of $0.97 and low estimates of $0.79.
Analysts are recommending an EPS of between $4.02 and $2.97 for the fiscal current year, implying an average EPS of $3.65. EPS for the following year is $3.98, with 6 analysts recommending between $4.71 and $2.8.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $643.61M this quarter.It ranges from a high estimate of $715.88M to a low estimate of $533.94M. As of the current estimate, Royalty Pharma plc’s year-ago sales were $852.9M, an estimated decrease of -24.50% from the year-ago figure.
A total of 5 analysts have provided revenue estimates for RPRX’s current fiscal year. The highest revenue estimate was $2.79B, while the lowest revenue estimate was $2.39B, resulting in an average revenue estimate of $2.62B. In the same quarter a year ago, actual revenue was $2.35B, up 11.10% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $2.87B in the next fiscal year. The high estimate is $3.23B and the low estimate is $2.57B. The average revenue growth estimate for next year is up 9.60% from the average revenue estimate for this year.
